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ABSTRACT
Peptoids are highly biocompatible pseudo-peptidic polyglycines with designable substituents on
the nitrogen atoms. The therapeutic and drug-carrying potential of these materials requires a
fundamental understanding of their interactions with lipid bilayers. In this work, we use
amphiphilic polypeptoids with up to 100 monomeric units where a significant fraction (26%) of
the nitrogen atoms are functionalized with decyl groups (hydrophobes) that insert into the lipid
bilayer through the hydrophobic effect. These hydrophobically modified polypeptoids (HMP)
insert their hydrophobes into lipid bilayers creating instabilities that lead to the rupture of vesicles.
At low HMP concentrations, such rupture leads to the creation of large fragments which
remarkably anchor to intact vesicles through the hydrophobic effect. At high HMP concentrations
all vesicles rupture to smaller HMP-lipid fragments of the order of 10 nm. We show that the
technique for such nanoscale polymer-lipid fragments can be exploited to sustain highly
hydrophobic drug species in solution. Using the kinase inhibitor, Sorafenib as a model drug, it is
shown that HMP-lipid fragments containing the drug can efficiently enter a hepatocellular
carcinoma cell line (Huh 7.5) indicating the use of such fragments as drug delivery nanocarriers.
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INTRODUCTION
Liposomes are a class of lipid vesicles that have shown significant promise as drug delivery
systems since the lipid bilayers mimic cell membranes leading to endocytosis by cells. Thus, these
systems can be designed to deliver hydrophilic molecules through encapsulation in the water core
of the liposome and hydrophobic drug species through integration into the lipid bilayer.

1-3

The

delivery of hydrophobic drug species is of specific relevance to cancer therapy

4-5

and

incorporation into the hydrophobic environment of lipid nanostructures such as liposomes,
bicelles, solid lipid nanoparticles represent new routes to delivery. 6-10
The interaction of vesicle lipid bilayers with a class of amphiphilic biomimetic polymers
known as polypeptoids is the subject of this study. Peptoids are a class of pseudo-peptidic
polyglycines with substituents on the nitrogen atoms.11-12 These polymers are of much interest due
to their highly designable structure and their structural similarity to peptides.13-14 Without
extensive hydrogen bonding and stereogenic centers along the backbone due to the N-substitution,
peptoids have a more flexible conformation and therefore enhanced resistance against
proteolysis.15-17 In addition, peptoids are biocompatible, and are therefore potentially useful in
biomedical applications such as drug delivery devices, tissue engineering materials, and smart
coatings.18-20
Our focus is the use of hydrophobically modified polypeptoids (HMPs) with up to 100
monomer units, and their interaction with lipid bilayers. The hydrophobic modification is the
functionalization of the nitrogen with alkyl groups which constitute the hydrophobes on an
otherwise water-soluble backbone. Thus, we specifically use the random copolymer shown in
Figure 1a, containing 74% of the neutral N-methoxyethyl groups (MeOEt) and 26% of N-n-decyl
(C10) groups along the backbone (Supporting Information S1, Scheme S1). The molecular weight
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Figure 1. (a) Structure of the hydrophobically modified polypeptoid (HMP) and the
phospholipid (L--phosphatidylcholine or PC) used to form vesicles. (b) Schematic showing
disruption of liposomes. At low HMP concentrations some of the liposomes are ruptured to
large fragments which attach to intact liposomes. At high HMP concentrations all liposomes
are ruptured to HMP-lipid fragments.
of the polymer is 13.9 kDa (Supporting Information S2, Figure S1) with a polydispersity index
(PDI) of 1.08 (Supporting Information S3, Figure S2). The polymer remains water soluble at this
level of hydrophobic substitution. The reason to use HMPs is based on the well-known
phenomenon of hydrophobe insertion into lipid bilayers through the hydrophobic effect.21-22 In
recent work from our laboratories we showed that HMPs significantly modify liposome
characteristics through such hydrophobe insertion. 23 Figure 1b is a synopsis of our earlier work
23

wherein we found that at low HMP concentrations some of the liposomes are ruptured by HMPs

into large fragments or HMP-lipid fragments. Interestingly, these fragments anchor to intact
liposomes to form additional layers on the remaining intact liposomes through a bridging effect
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where some of the hydrophobes are in one lipid layer while others are in the adjoining layer. HMP
thus serves as a connecting glue to bridge lipid bilayers. At higher HMP concentrations, all
liposomes are ruptured, resulting in the formation of smaller HMP-lipid fragments. 23
These observations are useful as they imply the ability to create small lipid-based structures
for drug delivery and the potential to attach such fragments to cell membranes thus facilitating
entry into the cell. Accordingly, the current study is the next level of understanding focusing on
the formation of HMP-lipid fragments and their potential to encapsulate hydrophobic drugs for
cell entry. Figure 2 schematizes the objectives of the current study to generate and characterize
HMP-lipid fragments. Path I is the generation of such fragments through rupturing of liposomes
preformed through well-established procedures of thin film plating of lipids, hydration of these
thin films to form large vesicles which are extruded to liposomes. While the formation of HMPlipid fragments by adding HMP to preformed liposomes has been established in our recent work,23

Hydration

Extrusion

+ HMP
(Path I) HMP-lipid
Fragments

Thin film
+ HMP
(Path II)

?
?

+ HMP in plated thin film + hydration
(Path III)
Figure 2. Schematic of generating HMP-lipid fragments through different paths. Path I
illustrates the generation of HMP-lipid fragments by interrupting lipid bilayers of extruded
liposomes. Path II shows the hypothesis to generate HMP-lipid fragments by interrupting lipid
bilayers of giant vesicles. Path III describes the hypothesis to form HMP-lipid fragments by
hydrating a thin film consisting of HMPs and lipids.
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we seek to establish the shorter routes to raft formation by deleting the extrusion step and directly
contacting the unextruded vesicles as shown in Path II. Path III describes an even more facile
approach where HMP is integrated into the plated thin films of lipids. The question then arises as
to whether hydration of the thin film will directly lead to raft formation. Finally, we characterize
the ability of these fragments to sustain a hydrophobic drug, Sorafenib, and show the potential of
these fragments to enter cells of a hepatocellular carcinoma cell line (Huh 7.5).
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EXPERIMENTAL SECTION
Materials
L-α-phosphatidylcholine (PC, >95%, from soy) and 1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(carboxyfluorescein) (PECF, ammonium salt, 99%) were purchased
from Avanti Polar Lipids. Deuterium oxide (>99.9%) was purchased from Cambridge Isotope
Laboratories. Dimethyl sulfoxide (99.5%) was purchased from Sigma-Aldrich. Sorafenib
(>99%) was purchased from Eton Bioscience (San Diego, CA). All chemicals were used as
received unless otherwise noted. N-methoxyethyl-N-carboxyanhydride (N-methoxyethyl NCA)
and N-decyl-N-carboxyanhydride (N-decyl NCA) were synthesized through previously reported
procedures as shown in Supporting Information Scheme S1.

23-25

Hoechst dye (H33342) was

purchased from Thermo Scientific, Germany. Huh-7.5 cells were obtained from the laboratory
of Dr. Srikanta Dash (Department of Pathology and Laboratory Medicine, Tulane University
Health Sciences Center, Louisiana) and the cells were cultured in Dulbecco's Modified Eagle
Medium (DMEM; Invitrogen, San Diego, CA) with high glucose supplemented with nonessential amino acids, sodium pyruvate, and 5% fetal bovine serum.
Methods
Synthesis and Characterization of Polypeptoids
The HMPs were synthesized through benzyl amine-initiated ring-opening polymerization
of the corresponding R-NCA monomers as reported previously.

23

Copolymerization of N-

methoxyehtyl NCA and N-decyl NCA yields a random copolymer of N-methoxyethyl glycine units
and N-decyl glycine units. The composition of the HMP backbone can be adjusted by controlling
the ratio of the two R-NCA monomers. In a typical synthesis, stock solutions of N-methoxyethyl
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NCA (1.3 mL, 0.4 M, 0.52 mmol) and N-decyl NCA (0.3 mL, 0.4 M, 0.13 mmol) in THF were
mixed together with a benzyl-NH2/THF stock solution (70 μL, 92.7 mM, 6.5 μmol). The mixture
was heated to 50 ºC for 48 hours. 1H NMR spectroscopy was used to check the conversion. The
polymer was precipitated out by excess hexanes, collected by filtration, and dried under vacuum
to obtain the final polypeptoid as a white solid (61.6 mg, 88.2% yield).
1

H NMR spectra of HMP (Supporting Information S2, Figure S1) were obtained using a

Bruker AV-400 Nanobay spectrometer at 298 K (400 MHz). Chemical shifts (δ) were referenced
to proton impurities in CD2Cl2. The exact composition of HMP was therefore determined. The
integration of the methylene groups in the backbone relative to the integration of benzyl end-group
yields a degree of polymerization (DP) of 100, while integration of methyl groups of N-decyl side
chains relative to the integration of benzyl end-group confirms a fraction of 26 mol % N-decyl
glycine units in the polymer backbone. The sample for size exclusion chromatography (SEC)
analysis was prepared by diluting 130 μL reaction mixture of HMP in 1 mL DMF containing 0.1
M LiBr. The analysis was carried out on an Agilent 1200 system equipped with three Phenomenex
5 μm, 300 × 7.8 mm2 columns [100 Å, 1000 Å and Linear (2)], a differential refractive index (DRI)
detector (Wyatt OptilabrEX) with a 690 nm light source, and a multi-angle light scattering detector
(Wyatt DAWN EOS, GaAs 30 mW laser at λ = 690 nm). 0.1 M LiBr in DMF solution was used
as the eluent. The flow rate was set at 0.5 mL min-1. The column and detector were operated at 22
ºC. The polydispersity index (PDI) was obtained with a calibration curve constructed by
polystyrene standards. A monomodal peak and a PDI of 1.08 indicate a narrow distribution of
polymer molecular weight (Supporting Information S3, Figure S2).
Preparation of Liposomes
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The liposomes were prepared by the thin-film hydration technique where the lipids are first
dissolved in an organic solvent and then evaporated to form a lipid thin film.26-27 Typically, 100
mg PC lipid was dissolved in 15 mL chloroform and methanol mixture (2/1, v/v) in a round bottom
flask. The solvent was then evaporated on a rotavapor (Buchi R-205) at room temperature at 100
mbar for 3 hours to form a thin lipid film. The film was further treated in vacuum at 6 mbar for 30
min to remove residual solvent. The formed thin lipid film was then hydrated using DI water at 50
ºC which yielded a suspension of large lipid vesicles. Fluorescent large vesicles were prepared by
adding 0.5 mg fluorescein-tagged lipid (PECF) to the organic solution of lipids followed by the
same manner. The vesicle suspension was extruded 21 times through polycarbonate membrane
with a pore size of 100 nm to downsize the unextruded vesicles into small unilamellar vesicles
with an average diameter of 100 nm. In all further discussion, the term liposome will apply to the
small extruded lipid vesicles. We recognize that the term liposome is general referring to lipid
vesicles, but for clarity we use the term unextruded vesicle to represent the large lipid vesicles
formed after hydration, and the term liposome to represent smaller lipid vesicles obtained after
extrusion. The liposome suspension was then diluted to 0.5 wt% (LIPO). To prepare drug
containing liposomes, Sorafenib was added to the lipid formulation and was dissolved together
with the lipids in the organic solvent followed by the same procedure.27 All concentrations are
reported in wt% unless otherwise mentioned.
We also prepared liposomes using a freeze-thaw technique to attempt to improve the
unilamellarity and size distribution. In the freeze-thaw technique. First, large vesicles were
prepared via thin film hydration method. After the hydration step the unextruded vesicles were
subjected to 10 cycles of freeze-thaw procedure to increase the volume of trapped aqueous phase
and thus reduce the lamellarity of the vesicles.28-29 Thus, the lipid suspension was transferred into
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polypropylene conical centrifuge tubes and was first submerged into a liquid nitrogen bath for 5
min. The suspension was then immediately plunged into water bath at 50oC for 5 min. The 10 min
period of submersion into liquid nitrogen and water was considered as one cycle and the procedure
was repeated for a total of 10 cycles. After the freeze-thaw the vesicle suspension was extruded
through 100 nm polycarbonate membrane to form liposomes.
Rupture of Liposomes using HMPs
The samples were prepared by mixing liposome stock solution (0.5%) with polypeptoid
stock solutions (0.5% and 1% in DI water) at 1:1 volume ratio. Samples were prepared from either
large unextruded vesicles (LVES) or extruded vesicles (liposomes -LIPO). The samples are
therefore denoted as LVES-HMP1, LVES-HMP2, LIPO-HMP1, and LIPO-HMP2, respectively,
where the number indicates the mass ratio of HMP to lipid. Liposomes incubated with DI water
was also prepared as the blank control, denoted as LIPO. Samples were incubated for at least 12
hours at room temperature prior to instrumental characterization. The HMP-LIP fragments (or
fluorescence-tagged fragments HMP-PECF) were also obtained by hydrating the thin film of
HMPs and lipids which were plated out together from the chloroform/methanol solution of HMPs
and lipids. To prepare drug loaded HMP-LIP fragment (HMP-LIP-SF), SF was added to the
chloroform/methanol solution of HMPs and lipids. D2O was used instead of H2O for 31P NMR and
1

H NMR spectra (Bruker AVANCE 300 298 K, 120 MHz).

Formation of HMP-lipid fragments by thin film hydration
To prepare HMP-lipid fragments through the thin film hydration process, HMP and lipid
were dissolved together in a chloroform/methanol (2/1, v/v) mixture. The weight ratio of HMP to
lipid was controlled at 2:1. The solvent evaporation step followed the same procedure and
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conditions as the general procedure to prepare lipid vesicles, resulting in a thin film consisting of
HMP and lipid at 2:1 ratio rather than the usual exclusively lipid thin film used to form vesicles
after hydration. The HMP-lipid thin film was then hydrated using DI water at room temperature,
to yield a clear solution. A suspension of Sorafenib (SF) loaded HMP-lipid fragments was also
made by adding SF to the chloroform/methanol solution of HMPs and lipids, followed by the same
evaporation and hydration steps as empty HMP-lipid fragments. In this study, the weight ratio of
lipid to SF was controlled at 1:0.024. We call this HMP-Lip-SF-P to recognize that the fragment
contains HMP, lipids and sorafenib that were directly formed by hydrating a plated out film of
these species.
Electron and Optical Microscopy Characterization
CryoTEM imaging was carried out on an FEI G2 F30 Tecnai TEM operating at 150 kV.
The sample for CryoTEM imaging was prepared on a lacey carbon coated copper grid (200-mesh,
Electron Microscopy Sciences) using an automated plunging station (FEI Vitrobot). 12 μL of the
sample solution was applied to the grid. The excess liquid was blotted by attached blotting papers
for 2 seconds to form a thin sample film which was immediately vitrified by being plunged into
liquid ethane. The grid with sample cryogenically immobilized was transferred onto a single tilt
cryo specimen holder for imaging. The optical microscopy images were taken with a Nikon A1
confocal microscope. 20 μL sample was pipetted onto a standard microscope slide. 488 nm laser
was used to excite the fluorescence-tagged samples.
Dynamic Light Scattering (DLS)
Dynamic light scattering (DLS) was used to characterize the size of the assemblies before
and after the addition of HMPs. Each DLS sample was diluted with NaCl solution to form a
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solution with 0.15% lipid and 50 mM NaCl, regardless HMP concentration. The solution was then
filtered through a PTFE filter (0.22 μm, Whatman) 3 times except for the unextruded vesicle
sample. The DLS particle sizing measurements were carried out on a Brookhaven Instrument
(90Plus PALS) which is equipped with a 640 nm laser. For each sample, 10 measurements of 100
s were performed at 25 °C, and the scattering signal was collected at 90°. The data were analyzed
using CONTIN method embedded in BIC Particle Solutions (v3.1) software. The lognormal
median diameter was reported as effective diameter or hydrodynamic diameter (DH).
Contact of HMP-Lipid Fragments with Living Cells for uptake
1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-carboxyfluorescein (PECF) was used
as the fluorescent probe to observe the fusion of the HMP-lipid fragment to Huh 7.5 (human
hepatocyte) cell line. The Huh 7.5 cells were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and incubated at 37°C
and 5% CO2. Cells were seeded in 6-well plates at a density of 1 × 105 cells per well. 5 µL of the
PECF-labeled HMP-lipid was added to the growth media. After 4 hours of incubation, the cells
were washed with PBS 3 times followed by cell fixation using 4 % paraformaldehyde in PBS.
Unbound and extracellular PECF-labeled HMP-lipid was rinsed off with sterilized PBS solution.
Following this step, Hoechst 33342 (Invitrogen) in PBS (2 μg mL-1) was used to stain the nucleus
of the cells for visualization.

30

Fluorescence images of cells were captured using an Olympus

IX70 microscope and an Olympus DP-71 digital camera. The negative control sample was
prepared by dissolving 50 mM PECF in DMSO and then diluted with the PBS buffer.

12

RESULTS AND DISCUSSION
Vesicle Rupture Induced by HMPs
The background for our current work lies in Figure 3 (a-c) which briefly summarizes our
findings on the interaction of HMP with fully extruded 100 nm liposomes.

23

Thus, Figure 3a

shows liposomes in the range of 100 nm that are made through the traditional methods of lipid
film formation, hydration to large lipid vesicles and subsequent extrusion to form relatively
uniform sized smaller vesicles which we term as liposomes. Upon adding HMPs to a level of 0.25
wt%, thes liposomes remarkably transform to layered structures (Figure 3b) where some of the
layers are incomplete (yellow arrows of Figure 3b). Through a combination of small-angle neutron
scattering and CryoTEM in our recent work, the observations can be understood.

23

First, the

insertion of a high local concentration of hydrophobes into liposome bilayers leads to the
disruption of some of the liposomes into large fragments. Since hydrophobe insertion into lipid
bilayers is a dynamic phenomenon, some of the hydrophobes on the polymer-lipid fragments come
free and reinsert into the bilayer of intact liposomes as shown schematically in Figure 1b. This
leads to the formation of the layered structures on liposomes, but the number density of liposomes
in solution is reduced (as was shown by the loss of intensity in the low q region of the SANS
scattering profile.23 With an increase in the concentration of the HMP, all liposomes become
disrupted into fragments. Thus, Figure 3c is a CryoTEM image of 0.25% extruded liposomes
incubated in 0.5% HMP, where all liposomes have been disrupted into small fragments in the 10
nm size range. The DLS data shown in Figure 3d additionally verifies this rupture with liposomes
of mean hydrodynamic diameter 126 nm breaking into fragments with mean hydrodynamic
diameter 10.8 nm and polydispersity index 0.16, indicating a moderately polydispersed size
distribution of the HMP-lipid fragments. Since these fragments represent broken-off lipid layers
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which are sustained in solution with HMP, we refer to them as HMP-lipid fragments. We note that
the edges of these fragments energetically cannot have exposed lipid tails and therefore expect that
the HMP polar groups cover these edges or that lipids rearrange at the edges to present a
hydrophilic exterior.

Figure 3. CryoTEM images of 0.25% extruded liposomes incubated with HMPs at different
concentrations and the size distributions of liposome and HMP-lipid fragment. (a) Unilamellar
liposomes with the size of 100 nm are formed without the addition of HMP (LIPO). (b)
Liposomes with multiple layers are formed with the addition of 0.25% HMP. Arrows point out
liposomes with multilayered structures. Scale bar in the inset is 50 nm. (c) Liposomes are
broken into small fragments with the addition of 0.5% HMP (HMP-LIP). (d) The size
distribution shows an effective liposome diameter of 126.4 nm, which shifts to 10.8 nm with
polydispersity index 0.16 after the addition of 0.5% HMP leading to the formation of HMP-LIP
fragment.
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The question that immediately arises is whether such HMP-lipid fragments can be obtained
without the extrusion step, thus starting from large vesicular structures as described by Path II in
Figure 2. Figure 4a is the CryoTEM image of micron-sized large vesicles formed directly from the
hydration step without any extrusion. After the addition of HMPs at the concentration of 0.25%,
the liposomes transform into multilayered structures, as shown in Figure 4b, with a clearer
visualization in the inset to Figure 4b. We again attribute this formation of multilayered structures
to the breakage of some of the large unextruded vesicles into HMP supported fragments which

Figure 4. CryoTEM images of 0.25% large unextruded vesicles incubated with HMP at
different concentrations and the size distributions of such large vesicles and HMP-lipid
fragments. (a) Large vesicles with the size of several microns are formed from thin film
hydration (LVES). (b) Large vesicles with multiple layers are formed with the addition of
0.25% HMP. The scale bars in the insets are 50 nm. (c) Vesicles are broken into small fragments
with the addition of 0.5% HMP. (d) The size distribution shows an effective vesicle diameter
of 3.3 μm, which shifts to 9.9 nm with polydispersity index 0.13 upon the addition of 0.5%
HMP leading to the formation of HMP-lipid fragments.

15

anchor to intact vesicles through hydrophobe insertion. Further addition of the HMP to the
concentration of 0.5% results in disruption of the entire population of large unextruded vesicles
into small fragments as shown in Figure 4c. We have also carried out DLS measurement of the
unextruded vesicular system before and after the addition of HMPs. The reduction in mean
hydrodynamic diameter from 3.5 μm prior to breakage to 9.9 nm with polydispersity index 0.13
after breakage again verifies this disruption of the liposomes into small HMP-lipid fragments.
The rupture of the large unextruded vesicles was also characterized by optical and
fluorescence microscopy. The vesicles were prepared from PC lipid with 0.3 mol% 1,2-dioleoyl-

Figure 5. Bright field and fluorescence microscopy of fluorescently tagged (0.3 mol%) large
unextruded vesicles and HMP-lipid fragments. (a) The top row shows the images of the large
unextruded vesicles prior to the addition of HMP. (b) The bottom row shows the complete
disappearance of vesicles and the fluorescence images show the presence of small lipid
structures throughout the field of vision. The scale bar is 100 µm in all images.

16

sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) (PECF) to provide the fluorescent tag
to the vesicles. The top row in Figure 5 shows the bright field and fluorescent images of the vesicles
which can be distinctly seen in optical microscopy. The vesicles have irregular shapes due to the
low melting transition temperature of PC lipids (-15 ºC) allowing shape flexibility at ambient
temperature. All vesicles emit fluorescence when irradiated at 488 nm indicating that they are
tagged by the PECF. The images in the bottom row show the complete disappearance of liposomes.
The fluorescence signal is spread over the entire background indicating the presence of small
fluorescent entities throughout the field of vision. These results provide further evidence of
unextruded vesicle rupture through the addition of HMP and the formation of HMP-lipid
fragments.
Vesicle rupture was also examined through
shows the

31

31

P and 1H NMR spectroscopy. Figure 6a

P NMR spectra of liposomes incubated with different concentrations of HMPs.

Without the addition of HMPs, the peak for phosphorus-31 is significantly line-broadened,
characteristic of phospholipids immobilized in the bilayer structure with slow rotational rates.

31

In the presence of 0.125% HMPs, the emergence of an isotropic peak is seen. With an increased
HMP concentration of 0.25%, the isotropic peak becomes more pronounced. With 0.5% HMPs
where all the liposomes are broken into HMP-lipid fragments, the isotropic peak reveals rotational
mobility of the small HMP-lipid fragments. At 0.125% HMP concentration, the emerged small
peak is due to the break-up of the lipid bilayer and the formation of the HMP-lipid fragments.
Because of the re-assembly of the fragment/HMP-lipid fragments onto the intact liposomes (the
formation of multilayered liposomes), the isotropic peak is weak, but nevertheless indicates that
there is rotational mobility of the lipids in the layers attached to bilayers of surviving intact
liposomes. The increase in sharpness with increasing HMP is symptomatic of generating additional
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fragments through disruption of more liposomes. At a HMP concentration of 0.5%, the strong and
sharp isotropic peak is a reflection of the rotational mobility of the fully disrupted liposomes. 32

Figure 6. (a) 31P NMR of vesicles with the addition of HMP at 0% (i), 0.125% (ii), 0.25% (iii),
and 0.5% (iv). (b) 1H NMR of vesicles with the addition of HMP at 0% (i), 0.125% (ii), 0.25%
(iii), and 0.5% (iv). Peak sharpening is observed from both 31P and 1H NMR spectra with the
increasing amount of HMP, indicating increased mobility of the lipid molecules.
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It is interesting to note that the normalized ratios of the integrated areas of the emergent
31

P resonances (0.22/0.53/1) are very close to the HMP weight ratios used to rupture liposomes

(0.125/0.25/0.5 or normalized to 0.25/0.5/1). If we assume that all liposomes are ruptured at the
0.5 wt% HMP level as indicated by the CryoTEM results, the normalized ratios of the integrated
areas imply a retention of 78 mol% of intact liposomes at an HMP concentration of 0.125 wt%
and a retention of 47 mol% of intact liposomes at an HMP concentration of 0.25 wt%. 1H NMR
spectra in Figure 6b also show the emergence of sharpened peaks of the protons in the alkyl chains
of the lipid molecules. The protons at 5.4-5.7 ppm (-CH2CHCHCH2-, a), 2.7-2.8 ppm (CHCH2CH-, b), and 1.9-2.2 ppm (-CHCH2CH2- and CH2CH2COO-, c) belong exclusively to the
lipid and do not interfere with the protons from HMP (Supporting Information S4, Figure S3).33
The sharpening of these peaks upon the addition of HMPs implies the formation of small fragments
of HMPs and phospholipids. The peak growth of other protons in the lipid molecules overlap with
HMP protons and are not specifically analyzed for enhanced rotational mobility through vesicle
rupture.
Hydrophobic Drug Encapsulation in the HMP-lipid Fragment
Sorafenib (SF) is a tyrosine protein kinase inhibitor and is currently FDA approved for the
treatment of renal cell carcinoma, thyroid cancer, and liver cancer. Sorafenib inhibits protein
kinases such as VEGFR, PDGFR, and the Raf family of kinases thus suppressing angiogenesis
and inducing apoptosis.

34

However, it is a highly hydrophobic compound with a very low

solubility in water of 0.2 μg mL-1.

35

This leads to large dose requirements with attendant

physiological and psychosomatic side effects.36 To improve the bioefficiency of Sorafenib
delivery, nanocarriers including liposomes have been used where Sorafenib has been solubilized
in the hydrophobic lipid bilayer. 27, 37
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In this work, we have used SF as a model component to demonstrate the ability of the
HMP-lipid fragment to encapsulate such hydrophobic drugs. Figure 7a is a visual observation of
various SF samples, (i) dispersed in water leading to rapid precipitation (SF) (ii) in large
unextruded vesicles (LVES-SF) (iii) in the extruded liposomes (LIPO-SF) and (iv, v) in HMPlipid fragments (HMP-LIP-SF and HMP-LIP-SF-P), respectively. We note the turbidity of the
large unextruded vesicle system (LVES-SF) and the translucency of the liposome suspension
containing SF (LIPO-SF). HMP-LIP-SF and HMP-LIP-SF-P are distinct samples that need
clarification. HMP-LIP-SF is obtained by adding 0.5 wt% HMP to a solution of large unextruded
vesicles containing SF and rupturing these vesicles to form the fragments containing SF. HMPLIP-SF-P is an alternative method of forming fragments where the HMP is added directly to the
lipid and SF in the chloroform-methanol solvent and plated out. Hydration is then carried out to
form suspensions of the fragments. The initial amount of the SF added to the system were kept
identical in all the samples. We note from visual observation that the HMP-LIP-SF-P solution is

Figure 7. HMP-lipid fragments to sustain SF solubility in the aqueous phase. (a) Photographs of
SF samples in water (SF), when sustained in large unextruded vesicle suspensions (LVES-SF),
when encapsulated in extruded 100 nm liposomes (LIPO-SF), when encapsulated in HMP-lipid
fragments by disrupting liposomes (HMP-LIP-SF), and when encapsulated directly in HMP-lipid
fragments through the hydration of plated thin films containing HMP in addition to lipid and SF
(HMP-LIP-SF-P). In all cases 0.5 wt% HMP was used to form the fragments (b) UV spectrum of
LVES-SF, LIPO-SF, HMP-LIP-SF, HMP-LIP-SF-P and supernatant of Sorafenib water
suspension (SF).
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clear indicating that the direct incorporation of HMP into the plated thin film prevents the
formation of vesicles upon hydration.
Figure 7b illustrates the SF UV-Vis absorbance spectra for all samples described in Figure
7a, from which the concentrations of SF in these suspensions can be determined. The supernatant
of each sample was diluted 20 times in DMSO to dissolve all components. Identical systems
without SF were also diluted 20 times in DMSO and used as the spectrometer reference samples
to subtract background absorbance. From Figure 7b, it is clear that the hydrophobic SF has
insignificant solubility in aqueous solutions. However, all other lipid containing systems are able
Table I. SF Encapsulated in Large Vesicles, Liposomes, and HMP-lipid Fragments
LVES-SF
LIPO-SF
HMP-LIP-SFa HMP-LIP-SF-Pb
CSF (µg mL-1)c
59.9
56.8
56.6
59.7
d
AE (%)
99.8
94.6
94.3
99.4
e
DL (%)
2.40
2.27
2.26
2.39
a, b: The concentration of HMP in the suspension is 0.5% by weight
c: Concentration of Sorafenib in the various suspensions. The initial concentration is 60 (μg
mL-1)
d: Association efficiency (AE). 𝐴𝐸% = 𝑊𝐴𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑒𝑑 𝐷𝑟𝑢𝑔 ⁄𝑊𝑇𝑜𝑡𝑎𝑙 𝐷𝑟𝑢𝑔 × 100%, where
𝑊𝐴𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑒𝑑 𝐷𝑟𝑢𝑔 is the weight of drug that is associated with lipid bilayer, and 𝑊𝑇𝑜𝑡𝑎𝑙 𝐷𝑟𝑢𝑔 is
the weight of drug initially added to the flask.
e: Drug loading (DL). 𝐷𝐿% = 𝑊𝐴𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑒𝑑 𝐷𝑟𝑢𝑔 ⁄𝑊𝐿𝑖𝑝𝑖𝑑 × 100%, where 𝑊𝐿𝑖𝑝𝑖𝑑 is the weight
of total lipid.
to sustain SF in solution to approximately the same extent. Table I quantifies the concentration of
Sorafenib in these systems together with the encapsulation efficiencies and drug loading capacities.
It is observed that the HMP-lipid fragments prepared by rupturing large unextruded vesicles
(HMP-LIP-SF) or by directly hydrating plated films containing lipids (HMP-LIP-SF-P) are able
to stabilize SF in solution to the same level as liposomes (LIPO-SF) and large vesicles (LVESSF).
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Figure 8 shows the CryoTEM images of the sample HMP-LIP-SF-P. The observation of
small entities indicates that integration of HMP into the plated film prevents the folding up of the
lipid layer into vesicles upon hydration. The DLS data of Figure 8b indicates the size

Figure 8. HMP-lipid fragments (HMP-LIP-SF-P) obtained from the thin film hydration method
(HMP/lipid = 2/1, w/w). The final HMP concentration in the solution is 0.5%. (a) CryoTEM
image of HMP-LIP-SF-P. The scale bar in the inset is 20 nm. No lipid vesicles are observed,
suggesting that HMP in the plated lipid thin film prevents the formation of lipid vesicles. (b)
Size distribution of LIPO-SF, HMP-LIP-SF and HMP-LIP-SF-P from DLS showing similarity
in the size range of HMP-lipid-sorafenib fragments prepared either through liposome
disruption (HMP-LIP-SF) or through hydration of the plated components.
characteristics of fragments prepared by disrupting Sorafenib containing vesicles (HMP-LIP-SF)
and prepared by hydrating plated out films containing lipid, HMP and Sorafenib (HMP-LIP-SFP). Both systems show similar size characteristics with mean of 11.2 nm and 9.1 nm, and PDI
values of 0.35 and 0.4 respectively. We note that there is a broader size distribution of the systems
containing SF in comparison to the SF-free systems of Figures 3 and 4.
The prevention of vesicle formation and the direct formation of small polymer+lipid
entities containing hydrophobic drugs is of direct interest in designing nanoscale carriers. We have
done experiments with decreasing the HMP level to determine an approximate HMP concentration
below which vesicle formation is unimpeded. The results are shown in Supporting Information S5
and we note that an HMP level of 0.25% (HMP/lipid ratio of 1/1) fully impedes vesicle formation
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while a lower HMP level of 0.125% allows some of the plated lipids to form vesicles upon
hydration. As a conservative estimate, an HMP/lipid ratio of 1/1 is necessary to entirely prevent
vesicle formation upon hydration, and to generate HMP-lipid fragments containing SF.
HMP-lipid Raft Attachment to Cells
Our objective is to be able to use these HMP-lipid fragments containing drug species to be
taken up into cells. In order to demonstrate the uptake of these fragments without disrupting cell
function, we have done studies on cell membrane fusion and entry without the drug species, using
a hepatocellular carcinoma cell line, Huh 7.5.
dissolving

a

fluorescent

lipid

1,

38

A negative control sample was prepared by

2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-

carboxyfluorescein (PECF) in DMSO at 50 mM which was then diluted with PBS. A Hoechst
33342 dye which binds only to the DNA was used for visualization of the nucleus.30 Figures 9a
and 9b show optical and fluorescence microscopy images respectively, of living cells incubated
with the negative control sample. In Figure 9b, the blue fluorescence indicates the cells are viable
when incubated with the negative control sample. Additionally, we notice the very weak green
fluorescence observed around the nucleus revealing the location of PECF molecules that have
entered the cell. Figure 9c and 9d show the corresponding optical and fluorescence microscopy
images of the cells incubated with the PECF-labeled HMP-lipid fragments prepared by hydrating
thin films of HMP, PECF and PC to obtain fragments in solution containing 0.25 wt% of HMP
and 0.25 wt% of lipids with the PECF component comprising 0.3 mol% of the total lipid content
(HMP-PECF+LIP-P). The final PECF concentration in HMP-PECF+LIP-P sample was kept the
same as that of the negative control sample. Cells incubated with HMP-PECF+LIP-P show an
intense green fluorescence in comparison with the negative control. The strong fluorescence
indicates efficient attachment and possible uptake of the HMP-PECF+LIP-P fragment by Huh 7.5
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cells. The discrete fluorescent dots in the cell may possible indicate integration of the fluorescent
lipid into the membranes of discrete organelles.39 But we do note that based on the fluorescence
images shown here, it is hard to determine whether the fragments are simply attached to the cell
membrane or are actually endocytosed into the cell. Nevertheless, we can ascribe the efficient
attachment of the fragments to hydrophobe insertion into the cell membrane. Initial cytotoxicity
results (not shown) indicate that while these fragments are not intrinsically cytotoxic to the cell,
the fragments with SF are extremely cytotoxic. Continuing work and a full study of the uptake of
Sorafenib containing fragments by Huh 7.5 cells in inducing cell death is in progress. The major

Figure 9. Optical and fluorescence microscopy of hepatocellular carcinoma cells (Huh 7.5 cell
line). Cells were stained with Hoechst in PBS (2 μg mL-1) for nucleus visualization. Each scale
bar presents 20 µm. (a and b) Hepatocellular carcinoma cells incubated with 1,2-dioleoyl-snglycero-3-phosphoethanolamine-N-carboxyfluorescein (PECF) alone. The sample was
prepared by dissolving PECF in DMSO at 50 mM followed by dilution with DI water. (c and
d) Hepatocellular carcinoma cells incubated with HMP-PECF-LIP-P. The sample was prepared
by hydrating the thin film containing 2.50 mg HMP, 2.49 mg soy PC lipid, and 0.01 mg PECF
using 1 mL DI water.
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aspects of the current study are simply to show that these HMP-lipid fragments generated through
hydration of HMP-lipid plated out layers or through rupture of vesicles, are capable of
encapsulating hydrophobic drug components and capable of attachment and entry to cells.
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CONCLUSIONS
This study indicates that the N-decyl hydrophobic side chains in the HMP backbone induce
structural transformations of vesicles, regardless of vesicle size. The disruption of vesicle bilayers
is a consequence of hydrophobe insertion into the bilayer at concentrations sufficient to create
local instabilities of the bilayer and thus rupture the bilayer. While similar dissolutions of lipid
bilayers can be accomplished with small molecule surfactants,

40-41

we note the significant

distinction here that entire fragments of bilayers can be broken off with such amphiphilic polymers
in contrast to the use of detergents where vesicles transform to mixed micelles of lipids and
detergents beyond a critical concentration of the detergent.42 The novelty of our observation is that
at low concentration of HMP (≤ 0.5%), the structures of either the liposome or the large vesicles
undergo changes from unilamellar structures to multilamellar structures, while at high
concentration of HMP (>0.5%), the lipid bilayers form HMP-lipid fragments. These materials add
to the class of small self-assembled structures that include mixed micelles and bicelles.
Such HMP-lipid fragments are promising candidates as nano-carriers for the delivery of
hydrophobic drugs. Our results indicate that highly hydrophobic drugs such as Sorafenib can be
directly incorporated into HMP-lipid fragments through integration of all components within a
thin film plating which is then hydrated to form the fragments, leading to a one-step, quantitative
encapsulation of Sorafenib in the HMP-lipid fragments. Uptake into cells appears to be fully
feasible and we note that such uptake may be aided by dynamically free hydrophobes on HMP
which may insert into cell membranes facilitating endocytic pathways for entry. Continuing studies
will seek to establish the fundamentals of such uptake and to exploit the hydrophobic effect
inherent in these nanoscale HMP-lipid fragments to enhance drug delivery.
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Supporting Information. S1. Synthetic routes of N-decyl NCA monomers, N-methoxyethyl NCA
monomers, and hydrophobically modified polypeptoids (HMP); S2: 1H NMR spectrum of HMP
in CD2Cl2; S3:SEC chromatograms of HMP; S4:1H NMR spectra of liposome, HMP, and HMPliposome mixture in D2O; S5:CryoTEM images of HMP-lipid fragments and vesicles formed
through plated thin film of HMP and lipids. S6: Liposomes prepared through the freeze-thaw
procedure as disrupted by HMP.
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